Search
Searching Content indexed under Life Sciences, Biotechnology & Nanotechnology by Goodwin Procter LLP ordered by Published Date Descending.
Links to Result pages
 
1  
 
Title
Country
Organisation
Author
Date
1
When Complying With HIPAA Is Not Enough: Tough New Medical Privacy Laws Are In Effect In Texas
While many covered entities and business associates are still adjusting to the changes to the Health Insurance Portability and Accountability Act ("HIPAA") ushered in by the Health Information Technology for Economic and Clinical Health Act, new privacy requirements that are more stringent than HIPAA recently entered into force in Texas.
United States
8 May 2012
2
Implementation Of The Biologics Price Competition And Innovation Act
A statutory and regulatory scheme to encourage the development of "biologics," drug products made in living organisms, has been a goal for more than a decade, and the Biologics Price Competition and Innovation Act ("BPCIA") was enacted on March 23, 2010.
United States
8 May 2012
3
Lessons From Mayo v. Prometheus: Assessing Patentability And Obtaining Patent Protection For "Laws Of Nature" Inventions
It is well established that "laws of nature, natural phenomena, and abstract ideas," themselves, are not patentable subject matter under §101 of the Patent Act, while an application of a law of nature, phenomena or abstract idea may be patentable.
United States
 
30 Mar 2012
4
Supreme Court Expands "Laws Of Nature" Exception To Patentability In Mayo V. Prometheus
This week, the U.S. Supreme Court reshaped the landscape of patent law with its long-awaited decision in Mayo Collaborative Services v. Prometheus Laboratories.
United States
 
30 Mar 2012
5
Landmark Healthcare Reform Legislation Creates Statutory Pathway For Biosimilar Biologics
On March 23, 2010, President Obama signed into law the Patient Protection and Affordable Care Act of 2010 ("PPACA"), Public Law No. 111-148.
United States
13 Apr 2011
6
Landmark Healthcare Reform Legislation Creates Statutory Pathway for Biosimilar Biologics
On March 23, 2010, President Obama signed into law the Patient Protection and Affordable Care Act of 2010 ("PPACA"), Public Law No. 111-148. This massive, groundbreaking piece of legislation contains, or the first time, a statutory pathway for licensure, or approval, of biological products that are biosimilar to, and possibly interchangeable with, earlier biological products (termed "reference products") licensed under the Public Health Service Act.
United States
7 Apr 2010
7
New Law Establishes Tax Credits for Qualifying Therapeutic Discovery Projects
The Patient Protection and Affordable Care Act, signed into law by President Obama on March 23, 2010, establishes a new tax credit that may be of significant benefit to small and mid-sized life sciences companies.
United States
2 Apr 2010
8
Massachusetts Issues Final “Gift Ban” Regulation Regarding Pharmaceutical And Medical Device Manufacturer Conduct
Massachusetts has issued a final regulation implementing a sweeping new regime affecting the way biotechnology, pharmaceutical and medical device companies can market their products within the Commonwealth.
United States
25 Mar 2009
9
Massachusetts Life Sciences Center Launches New Tax Incentive And Early-Stage Investment Programs
The Massachusetts Life Sciences Center (the “MLSC”), a quasi-public agency tasked with implementing the State’s $1 billion Life Sciences Initiative, is now accepting online applications for its Life Sciences Tax Incentive Program and its Life Sciences Accelerator Program.
United States
2 Feb 2009
10
EPA Takes First-Ever Regulatory Actions Aimed At Potential Nanomaterial Risks
The U.S. Environmental Protection Agency (“EPA”) has taken its first clear steps to directly regulate the potential environmental, health and safety (“EHS”) risks associated with the manufacture and use of nanomaterials.
United States
10 Nov 2008
11
Top 10 Issues In Licensing Technology From Universities
Many successful products on the market today began as embryonic inventions in university research laboratories. Gene splicing, magnetic resonance imaging and atomic microscopy, for example, all had their beginnings in the university setting.
United States
 
1 May 2007
12
Stem Cells: Their Promise, Their Problems
Stem cells have been in the news a great deal recently, both for their medical promise and the difficult ethical questions the use of embryonic stem cells present. Here we discuss some of the science, medical treatments, ethics, IP concerns and business of stem cells.
United States
 
9 Mar 2005
Links to Result pages
 
1